Navigation Links
U-Iowa improves delivery of cancer-fighting molecules
Date:8/27/2009

Small interfering RNA (siRNA), a type of genetic material, can block potentially harmful activity in cells, such as tumor cell growth. But delivering siRNA successfully to specific cells without adversely affecting other cells has been challenging.

University of Iowa researchers have modified siRNA so that it can be injected into the bloodstream and impact targeted cells while producing fewer side effects. The findings, which were based on animal models of prostate cancer, also could make it easier to create large amounts of targeted therapeutic siRNAs for treating cancer and other diseases. The study results appeared online Aug. 23 in the journal Nature Biotechnology.

"Our goal was to make siRNA deliverable through the bloodstream and make it more specific to the genes that are over expressed in cancer," said the study's senior author Paloma Giangrande, Ph.D., assistant professor of internal medicine and a member of Holden Comprehensive Cancer Center.

In previous research completed at Duke University, Giangrande's team showed that a compound called an aptamer can be combined with siRNA to target certain genes. When the combined molecule is directly injected into tumors in animal models, it triggers the processes that stop tumor growth. However, directly injecting the combination into tumors in humans is difficult.

In the new study, the researchers trimmed the size of a prostate cancer-specific aptamer and modified the siRNA to increase its activity. Upon injection into the bloodstream, the combination triggered tumor regression without affecting normal tissues.

Making the aptamer-siRNA combination smaller makes it easier to produce large amounts of it synthetically, Giangrande said.

The team also addressed the problem that large amounts of siRNA are needed since most of it gets excreted by the kidneys before having an effect. To keep siRNA in the body longer and thereby use less of it, the team modified it using a process called PEGlyation.

"If you want to use siRNA effectively for clinical use, especially for cancer treatment, you need to deliver it through an injection into the bloodstream, reduce the amount of side effects and be able to improve its cost-effectiveness. Our findings may help make these things possible," Giangrande said.

Although the current study focused on prostate cancer, the findings could apply to other cancers and diseases. Giangrande said the next step is to test the optimized aptamer-siRNA compound in a larger animal model.


'/>"/>

Contact: Becky Soglin
becky-soglin@uiowa.edu
319-356-7127
University of Iowa
Source:Eurekalert  

Related biology news :

1. Exercise improves thinking, reduces diabetes risk in overweight children
2. Endobronchial valve significantly improves emphysema
3. Teamwork improves learning and career success
4. New clinical data shows chromium picolinate improves cognitive function
5. Stem-cell transplantation improves muscles in MD animal model, UT Southwestern researchers report
6. Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
7. New surgery improves head and neck cancer treatment
8. More than words: childbirth training change improves safety, cuts unnecessary procedures
9. CAPHOSOL relieves oral mucositis and improves quality-of-life in cancer patients
10. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
11. Pictures of hot fudge sundaes arouse: Understanding emotions improves our food choices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
U-Iowa improves delivery of cancer-fighting molecules
(Date:1/4/2017)... of attendees at this year,s International Consumer Electronics Show (CES), A&D ... and services, will be featuring its new line of ULTRA CONNECT ... CES Exhibit Suite , the new upper arm and wrist smart blood ... product platform.  Continue Reading ... ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ), ... HealthCare, and Finance sectors announced today that Leaders in Community Alternatives ... deploy a community-based supportive services program to reduce recidivism in a ... its presence in the state. ... This new program, which is expected to commence in ...
(Date:12/16/2016)... Dec. 16, 2016   IdentyTechSolutions America LLC ... products and solutions and a cutting-edge manufacturer of ... it is offering seamless, integrated solutions that comprise ... products. The solutions provide IdentyTech,s customers with combined ... facilities from crime and theft. "We ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... , January 18, 2017 According to a new market ... Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic and Research ... to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... ... January 18, 2017 , ... Executive search firm Slone Partners ... commitment to the advancement of the clinical trials segment. Hosted in Miami, this ... trial planning and management. , As executive talent specialists in the industries ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... paralysis, today announced that it has submitted a 510(k) to the FDA, requesting ... utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The submission marks ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the leading ... by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue of ... joined uBiome in October 2016 from her previous position at Stanford University School ...
Breaking Biology Technology: